Reviewer's report

Title: Assessment of Effectiveness Measures in Patients with Schizophrenia Initiated on Risperidone Long-acting Therapy: the SOURCE Study Results

Version: 1 Date: 26 October 2010

Reviewer: José Manuel Olivares

Reviewer's report:

The paper provides interesting data about the use of long-acting risperidone in patients with schizophrenia in real world conditions, thus permitting to gather information about conditions usually excluded from clinical trials. It provides data about the effectiveness of Risperidone long-acting injectable on clinically relevant outcomes such as patients's functionality and health-related quality. Obviously, the type of study have its limitations. However, I would recommend the paper to be published as it is.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have been involved in advisory boards organized by Eli Lilly, Janssen-Cilag and AstraZeneca and I have been the recipient of honoraria from Janssen-Cilag, Lundbeck, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis and Pfizer in the last five years.